In A549 lung cancer cells, a PON2 deficit resulted in reduced cell death and caspase-3/7 activation upon C12 treatment, while in PON2-deficient cells, actinomycin D and tunicamycin exposure further bolstered cell mortality (Zhao et al. 2016). This evidence concerns the gene PON2 and lung carcinoma.